AR090884A1 - Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc - Google Patents
Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gccInfo
- Publication number
- AR090884A1 AR090884A1 ARP130101458A ARP130101458A AR090884A1 AR 090884 A1 AR090884 A1 AR 090884A1 AR P130101458 A ARP130101458 A AR P130101458A AR P130101458 A ARP130101458 A AR P130101458A AR 090884 A1 AR090884 A1 AR 090884A1
- Authority
- AR
- Argentina
- Prior art keywords
- gcc
- same
- antibody molecules
- directed therapy
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Se describen anticuerpos y fragmentos de enlace de antígeno de anticuerpos que enlazan GCC (Guanilil ciclasa C). También proporciona métodos de diagnóstico para identificar pacientes quiénes deben recibir una terapia dirigida a GCC utilizando los anticuerpos anti-GCC proporcionados en la presente. Ácido nucleico, vector, célula huésped, método para producir el anticuerpo, composición farmacéutica y kit.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261639376P | 2012-04-27 | 2012-04-27 | |
PCT/US2013/038542 WO2013163633A1 (en) | 2012-04-27 | 2013-04-27 | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AR090884A1 true AR090884A1 (es) | 2014-12-10 |
Family
ID=49477498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101458A AR090884A1 (es) | 2012-04-27 | 2013-04-29 | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc |
Country Status (41)
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201407757XA (en) | 2009-10-23 | 2015-01-29 | Millennium Pharm Inc | Anti-gcc antibody molecules and related compositions and methods |
CA2928043A1 (en) * | 2013-10-21 | 2015-04-30 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
JP6496962B2 (ja) | 2014-02-14 | 2019-04-10 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーBioVentures, LLC | アセトアミノフェン−タンパク質付加物およびその使用方法 |
CA2967037A1 (en) | 2014-12-03 | 2016-06-09 | Bioventures, Llc | Anti-acetaminophen antibodies and acetaminophen protein adducts |
US11090383B2 (en) | 2015-10-01 | 2021-08-17 | Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
CN117038018A (zh) * | 2017-12-06 | 2023-11-10 | 文塔纳医疗系统公司 | 存储和检索数字病理学分析结果的方法 |
US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
EP3846788A1 (en) * | 2018-09-05 | 2021-07-14 | Universiteit van Amsterdam | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
EP4159860A1 (en) * | 2020-06-02 | 2023-04-05 | Teijin Pharma Limited | Anti-igf-1 receptor humanized antibody |
CR20230245A (es) * | 2020-12-17 | 2023-09-01 | Parasol Biotech Ltd | Moléculas de unión a gucy2c y sus usos |
WO2024067762A1 (en) * | 2022-09-28 | 2024-04-04 | Nanjing Legend Biotech Co., Ltd. | Antibody and chimeric antigen receptors targeting gcc and methods of use thereof |
CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
ES2216004T3 (es) | 1993-10-26 | 2004-10-16 | Thomas Jefferson University | Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas. |
US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
WO1997042220A1 (en) | 1996-05-03 | 1997-11-13 | Thomas Jefferson University | Metastatic colorectal cancer vaccine |
US6602659B1 (en) | 1996-05-03 | 2003-08-05 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
US20020012931A1 (en) | 2000-03-27 | 2002-01-31 | Waldman Scott A. | High specificity marker detection |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
PT1377314E (pt) | 2001-01-26 | 2012-01-02 | Inhibitex Inc | Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções |
PT1379224E (pt) | 2001-03-29 | 2009-10-22 | Synergy Pharmaceuticals Inc | Agonistas do receptor da guanilato ciclase para o tratamento de inflamação de tecidos e carcinogénese |
CZ303450B6 (cs) | 2001-04-13 | 2012-09-19 | Biogen Idec Ma Inc. | Protilátky k VLA-1, kompozice je obsahující a nukleové kyseliny, které je kódují, zpusob stanovení hladiny VLA-1 a použití pri lécení imunologického onemocnení |
CA2471849A1 (en) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Antibodies against the muc18 antigen |
US20040110933A1 (en) | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2004071436A2 (en) | 2003-02-10 | 2004-08-26 | Thomas Jefferson University | The use of gcc ligands |
EP2357237A1 (en) | 2003-05-14 | 2011-08-17 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
EP2722060A3 (en) | 2004-06-25 | 2015-01-07 | Thomas Jefferson University | Guanylyl cyclase C ligands |
ES2371083T3 (es) | 2004-12-21 | 2011-12-27 | Medimmune Limited | Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos. |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
KR101709488B1 (ko) | 2007-08-10 | 2017-02-24 | 리제너론 파아마슈티컬스, 인크. | 인간 신경성장인자에 대한 고친화성 인간 항체 |
CN101889021B (zh) * | 2007-08-10 | 2016-06-08 | 詹森生物科技公司 | 作为疾病指标的免疫球蛋白裂解片段与用于检测和结合所述片段的组合物 |
KR101651690B1 (ko) * | 2007-11-30 | 2016-08-26 | 제넨테크, 인크. | Vegf 다형성 및 항―혈관신생 요법 |
CA2760050A1 (en) | 2008-05-13 | 2009-11-19 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
AU2009256156B2 (en) | 2008-06-04 | 2014-09-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
US9090695B2 (en) * | 2008-12-03 | 2015-07-28 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
PL2881402T3 (pl) * | 2009-02-12 | 2017-10-31 | Cell Signaling Technology Inc | Ekspresja zmutowanej ROS w ludzkim raku wątroby |
AU2010217160C1 (en) | 2009-02-25 | 2015-07-02 | Diagnocure Inc. | Method for detecting metastasis of GI cancer |
US8598188B2 (en) * | 2009-03-12 | 2013-12-03 | Kinki University | Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer |
US20120225099A1 (en) | 2009-06-15 | 2012-09-06 | Thomas Jefferson University | Compositions for and methods of activating guanylyl cyclase c |
EP3444333A1 (en) | 2009-10-22 | 2019-02-20 | Thomas Jefferson University | Cell-based anti-cancer compositions and methods of making and using the same |
SG10201407757XA (en) * | 2009-10-23 | 2015-01-29 | Millennium Pharm Inc | Anti-gcc antibody molecules and related compositions and methods |
JP2013534515A (ja) * | 2010-06-01 | 2013-09-05 | モナシュ ユニバーシティ | プロセシングされていない受容体型チロシンキナーゼc−METに対する抗体 |
EP2603239A2 (en) * | 2010-08-13 | 2013-06-19 | F.Hoffmann-La Roche Ag | Neuropilin as a biomarker for bevacizumab combination therapies |
US20150086481A1 (en) | 2011-07-28 | 2015-03-26 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
US20140356383A1 (en) * | 2013-02-28 | 2014-12-04 | Ole Petter Veiby | Administration of an anti-gcc antibody-drug conjugate and a dna damaging agent in the treatment of cancer |
-
2013
- 2013-04-27 PT PT137820619T patent/PT2841575T/pt unknown
- 2013-04-27 EA EA201491977A patent/EA034689B1/ru unknown
- 2013-04-27 PL PL13782061T patent/PL2841575T3/pl unknown
- 2013-04-27 SA SA113340502A patent/SA113340502B1/ar unknown
- 2013-04-27 MA MA37569A patent/MA37569B1/fr unknown
- 2013-04-27 WO PCT/US2013/038542 patent/WO2013163633A1/en active Application Filing
- 2013-04-27 CA CA2871614A patent/CA2871614C/en active Active
- 2013-04-27 ES ES13782061T patent/ES2749181T3/es active Active
- 2013-04-27 SG SG11201406855TA patent/SG11201406855TA/en unknown
- 2013-04-27 PE PE2014001908A patent/PE20142322A1/es active IP Right Grant
- 2013-04-27 CN CN201380033309.4A patent/CN104395470B/zh active Active
- 2013-04-27 LT LTEP13782061.9T patent/LT2841575T/lt unknown
- 2013-04-27 AU AU2013251312A patent/AU2013251312B2/en active Active
- 2013-04-27 SI SI201331582T patent/SI2841575T1/sl unknown
- 2013-04-27 HU HUE13782061A patent/HUE046404T2/hu unknown
- 2013-04-27 DK DK13782061.9T patent/DK2841575T3/da active
- 2013-04-27 UA UAA201412715A patent/UA117910C2/uk unknown
- 2013-04-27 RS RSP20191239 patent/RS59370B1/sr unknown
- 2013-04-27 MX MX2014013081A patent/MX362020B/es active IP Right Grant
- 2013-04-27 KR KR1020147032890A patent/KR102046435B1/ko active IP Right Grant
- 2013-04-27 US US13/872,080 patent/US9000129B2/en active Active
- 2013-04-27 GE GEAP201313644A patent/GEP201706737B/en unknown
- 2013-04-27 EP EP13782061.9A patent/EP2841575B1/en active Active
- 2013-04-27 JP JP2015509208A patent/JP6472746B2/ja active Active
- 2013-04-27 ME MEP-2019-257A patent/ME03560B/me unknown
- 2013-04-27 MY MYPI2014703176A patent/MY188442A/en unknown
- 2013-04-27 NZ NZ701601A patent/NZ701601A/en unknown
- 2013-04-29 TW TW102115363A patent/TWI631137B/zh active
- 2013-04-29 AR ARP130101458A patent/AR090884A1/es active IP Right Grant
-
2014
- 2014-10-23 ZA ZA2014/07723A patent/ZA201407723B/en unknown
- 2014-10-23 IL IL235307A patent/IL235307B/en active IP Right Grant
- 2014-10-24 DO DO2014000242A patent/DOP2014000242A/es unknown
- 2014-10-24 PH PH12014502399A patent/PH12014502399B1/en unknown
- 2014-10-24 TN TN2014000454A patent/TN2014000454A1/fr unknown
- 2014-10-27 CL CL2014002911A patent/CL2014002911A1/es unknown
- 2014-10-27 CR CR20140497A patent/CR20140497A/es unknown
- 2014-11-25 EC ECIEPI201428523A patent/ECSP14028523A/es unknown
- 2014-11-26 CO CO14260074A patent/CO7280144A2/es unknown
-
2015
- 2015-02-27 US US14/634,438 patent/US9273146B1/en active Active
- 2015-09-02 HK HK15108592.8A patent/HK1208049A1/xx unknown
-
2016
- 2016-01-19 US US15/000,950 patent/US20160130344A1/en not_active Abandoned
-
2017
- 2017-04-26 JP JP2017087084A patent/JP6517267B2/ja active Active
-
2019
- 2019-09-18 HR HRP20191690TT patent/HRP20191690T1/hr unknown
- 2019-09-24 CY CY20191101005T patent/CY1122557T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR090884A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
PH12021550083A1 (en) | Human anti-tau antibodies | |
CY1121934T1 (el) | Αντισωματα anti-fcrn | |
CY1123515T1 (el) | Μεθοδοι αγωγης μιας ταυπαθειας | |
CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
AR091649A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos | |
GT201300306A (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
AR088514A1 (es) | Inmunoligantes biespecificos dirigidos contra tnf | |
BR112015012933A2 (pt) | proteínas de ligação ao antígeno bcma | |
CO7151488A2 (es) | Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos | |
AR088512A1 (es) | Anticuerpos dirigidos contra el tnf | |
AR089178A1 (es) | Anticuerpos anti-il-36r | |
BR112013021134A8 (pt) | Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
UY32971A (es) | Proteínas de unión al antígeno de la il-23 humana | |
EA201490825A1 (ru) | Tdp-43-специфически связывающие молекулы | |
AR063840A1 (es) | Anticuerpos humanos monoclonales para btla y metodos de uso | |
BR112014020826A8 (pt) | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado | |
AR090923A1 (es) | Anticuerpos anti-il-23 | |
CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
BR112014003999A2 (pt) | anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
DOP2013000218A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
UY33274A (es) | Proteínas de unión a basigina | |
BR112014032916A2 (pt) | anticorpos anti-fármacos e usos destes para o monitoramento de fármaco |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |